Navigation Links
Trial Set to See if Drug Can Prevent Alzheimer's
Date:5/15/2012

TUESDAY, May 15 (HealthDay News) -- Researchers are preparing to test an experimental drug in people genetically primed to develop Alzheimer's disease.

The best-scenario hope is that the drug will lead to a way of preventing the progressive brain-wasting disease, and to a better understanding of its destructive processes, U.S. officials announced Tuesday.

The study volunteers will include some Americans as well as 300 members of an extended Colombian family -- some only 30 years old -- thought to have more relatives with Alzheimer's than any family in the world, The New York Times reported.

None of the study participants will have any signs of dementia at the start of the five-year, $100 million study. Dr. Francis Collins, director of the U.S. National Institutes of Health, said this study is "the first to focus on people who are cognitively normal but at very high risk for Alzheimer's disease," according to the Times.

People with a certain genetic mutation are predestined to develop early-onset Alzheimer's. For this group, dementia typically sets in by about age 50, and signs of thinking and memory problems are evident by age 45.

It's hoped that the study will reveal clues to the development and treatment of Alzheimer's -- the leading cause of dementia -- in other people as well, not just those with what doctors call early-onset Alzheimer's.

The trial is designed to test the widely held theory that Alzheimer's is caused by a buildup in the brain of a protein called beta amyloid. The experimental drug -- crenezumab, which is made by Genentech of South San Francisco -- is designed to attack the formation of beta amyloid plaque.

Currently, there is no cure for Alzheimer's, which affects 5.4 million Americans, or one in eight older adults. And as the baby boom generation ages, those numbers are expected to balloon, creating a major public health crisis in the United States.

Experts on Alzheimer's disease welcomed the announcement of the drug trial.

"This strategy is our best chance of success at Alzheimer's disease," said Dr. Sam Gandy, associate director of the Alzheimer's Disease Research Center at Mount Sinai School of Medicine and director of Mount Sinai's Center for Cognitive Health, in New York City.

"The main challenges are how to identify who is on their way to [Alzheimer's disease], how early we need to begin prior to symptoms, and how long we will have to run the trial before we can see whether the drug delays onset," added Gandy, chairman emeritus of the Alzheimer's Association's National Medical and Scientific Advisory Council.

More information

For more about Alzheimer's disease, visit the Alzheimer's Association.

-- HealthDay staff

SOURCES: Sam Gandy, M.D., Ph.D., Mount Sinai Chair in Alzheimer's Disease Research, and professor of neurology and psychiatry, and director, Mount Sinai Center for Cognitive Health, and associate director, Mount Sinai Alzheimer's Disease Research Center, Mount Sinai School of Medicine, New York City; The New York Times


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Palpitations are predictive of future atrial fibrillation
2. New Weight-Loss Drug Shows Promise in Trial
3. US spends far more for health care than 12 industrialized nations, but quality varies
4. Analysis Finds Clinical Trials Often Small, of Poor Quality
5. URMC clinical trial tests new regimen for hypertension
6. Brain Tumor Vaccine Shows Promise in Early Trial
7. Cancer trial information leaflets not fit for purpose- new study
8. Statin Alternative Looks Promising in Early Trials
9. Study: Low bone density medications may have protective effect on endometrial cancer
10. $4.2 million grant helps plan, launch first Alzheimers prevention trials
11. Cytori breast reconstruction cell therapy trial results published
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/18/2017)... ... August 18, 2017 , ... Rollon Skin ... anti-aging skincare solutions, recently announced the launch of two new skincare products, ... yet effective alternative to expensive plastic surgery or in-patient cosmetic dermatological procedures. , ...
(Date:8/18/2017)... ... ... “Steve the Snake”: an entertaining and moral-based short story about an unkind ... Harold Flash Haskins Jr., a husband, father and grandfather who served as a U.S. ... moral-based short stories for children and teens. My goal is to teach kids to ...
(Date:8/17/2017)... Waltham, Mass (PRWEB) , ... August 17, 2017 ... ... high use by health care organizations and considered extremely effective, very effective, or ... “Leading Physicians and Physician Leadership”. , NEJM Catalyst Insights Reports are based on ...
(Date:8/17/2017)... ... 17, 2017 , ... Industry CEOs, life science leaders, influential ... This off-the-record networking forum of the Boston Biotech Conference series will be held ... leaders and decision makers will discuss issues facing the development of anti-infective, antiviral, ...
(Date:8/17/2017)... City, Utah (PRWEB) , ... August 17, 2017 , ... ... share how to efficiently and effectively grow a dental practice in a competitive market ... hours of dental C.E. that could just transform you and your practice.” says Daniel ...
Breaking Medicine News(10 mins):
(Date:8/2/2017)... , Aug. 2, 2017 Fenita ... Who as a Pinnacle Lifetime Professional in the ... Account Manager at Turing Pharmaceuticals, AG. Her skills ... and relationship building.                ... than 25 years of experience as a highly ...
(Date:8/1/2017)... --  CerSci Therapeutics , a non-opioid drug development firm ... received notice from the National Institute on Drug Abuse ... it has been awarded a Direct-to-Phase II Small Business ... with an additional $1,000,000 to follow in 2018. These ... their lead non-opioid drug candidate CT-044 to the Food ...
(Date:7/28/2017)... -- Hill-Rom Holdings, Inc. ("Hill-Rom") (NYSE: HRC), today announced ... 30, 2017, and updated its financial outlook for fiscal ... the fiscal third quarter, Hill-Rom reported earnings of $0.09 ... in the prior-year period. These results reflect after-tax special ... primarily related to the non-cash write-down of assets associated ...
Breaking Medicine Technology: